bone loss semaglutide New studies have raised fresh alarms about the popular “weight-loss drug” Ozempic, revealing it may accelerate and weaken skeletal health in users. Research published in 2025–2026 shows patients on Ozempic May Reduce Bone Density;

Authorities like Exercise New Zealand are sounding the alarm about the hidden health risks that may accompany certain weight loss drugs.

These eight countries are particularly significant due to the diversity they offer across several critical factors: regulatory approaches, obesity prevalence, GPD per capita, population size and status as global manufacturing hubs

Howard Weintraub of NYU Langones Center for the Prevention of Cardiovascular Disease weighs in on semaglutide and the SELECT trial

Changes made after this cut-off will not be accepted

Retatrutide by Geno X provides high quality research-grade peptide for fat loss studies with fast Australia-wide delivery

More patients are coming forward, claiming they lost thousands of dollars after purchasing what they believed were GLP-1 weight-loss drugs.